CancerDrs Find care

Brain Cancer clinical trials in District of Columbia

22 actively recruiting brain cancer trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…

Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

Sponsor: Hoffmann-La Roche
NCT ID: NCT05503264
Sites in District of Columbia:
  • Childrens National Health Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. …

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
NCT ID: NCT06712875
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Network

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…

Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherap…

Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04323046
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Industry

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neu…

Sponsor: Valent Technologies, LLC
NCT ID: NCT04337177
Sites in District of Columbia:
  • Children's National Research Institute - Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from …

Sponsor: Children's National Research Institute
NCT ID: NCT06193759
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other

Targeted Pediatric High-Grade Glioma Therapy

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligi…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05839379
Sites in District of Columbia:
  • Children's National Medical Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during su…

Sponsor: University of California, San Francisco
NCT ID: NCT05057702
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other

International Rare Brain Tumor Registry

The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed wi…

Sponsor: Children's National Research Institute
NCT ID: NCT05697874
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT03223922
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients

The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduc…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05658731
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other

Pediatric Radiation Therapy Registry

The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the long-term…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07129317
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Visual Plasticity Following Brain Lesions

The VIBRANT (Vision Improvement through Behavioral Rehabilitation And Neuroplasticity Training) study is a prospective, double-blind, crossover design (within-subject) in participants with homonymous hemianopia-a type of visual field loss …

Sponsor: Georgetown University
NCT ID: NCT07105358
Sites in District of Columbia:
  • Georgetown University Medical Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Feasibility/Acceptability of Attentional-Control Training in Survivors

This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ag…

Sponsor: Children's National Research Institute
NCT ID: NCT05528939
Sites in District of Columbia:
  • Children's National Hospital — Washington D.C., District of Columbia

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20